Thursday, 16 July 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 16 July 2026
News

Aussie deal struck on biosimilar

Posted 16 July 2026 AM

A languishing drug may restart the process for PBS listing with Samsung Bioepis and Organon announcing they have expanded their Development and Commercialisation Agreement to include a fourth biosimilar in Australia.

"We are proud to build on our longstanding partnership with Organon to expand the availability of our biosimilar portfolio for Australian patients," Samsung Bioepis Vice President and Head of Commercial Strategy for International Markets, Jinhan Chung, said. "This expanded agreement reflects Samsung Bioepis' enduring commitment to widening global access to biosimilars."

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (23)

Access & Reimbursement (1)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (4)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.